






The prevalence of lipodystrophy in HIV infected patients in Dr. Kariadi 
Hospital was 21.7% in stavudine group and the prevalence of dyslipidemia was 
82.6% in stavudine group. Most patients in stavudine group were reported with 
lipohypertrophy of abdomen (34.8%) and decreased HDL-c level (52.2%).  
From this study it can be concluded that: 
1. Stavudine administration was not significantly associated with lipodystrophy 
among HIV-infected patients in Dr. Kariadi Hospital Semarang. 
2. Stavudine administration was significantly associated with dyslipidemia 
among HIV-infected patients in Dr. Kariadi Hospital Semarang. 
3. Sex was siginificantly associated with lipodystrophy among HIV-infected 
patients with stavudine administration in Dr. Kariadi Hospital Semarang while 
age, CD4 count, and duration of treatment were not. 
4. Sex, age, CD4 count, and duration of treatment were not significantly 
associated with dyslipidemia among HIV-infected patients with stavudine 





1. Stavudine should be phased out as first-line drugs in HIV treatment in Dr. 
Kariadi Hospital Semarang due to its metabolic side effects such as 
dyslipidemia and lipodystrophy.  
2. Zidovudine, abacavir or tenofovir should be used to replace stavudine due to 
its ability to improve disturbed lipid profiles in patients with stavudine 
associated dyslipidemia.  
3. Advances studies should be conducted to determine the main mechanism 
responsible in stavudine associated dyslipidemia and lipodystrophy in HIV-
infected patients.  
 
 
 
